The acquisition marked Astrazeneca’s formal embrace of biologicals. Today the Medimmune name was dropped.
Johnson & Johnson's esketamine should get approved in depression, but a safety plan requiring supervision raises questions about its commercial promise.
In a constrained pricing environment a volume play could help sales of Lilly's Emgality as it takes on Amgen’s Aimovig and Teva’s Ajovy.
The French company has taken a look at its R&D portfolio, and made some radical changes in oncology and diabetes.
As Glaxosmithkline manoeuvres to become a major player in cancer, it backs Icos among other novel mechanisms.
Despite manufacturing struggles, Novartis still expects Kymriah to become a blockbuster.
The latest setback to Bristol-Myers Squibb’s first-line lung cancer plan sees it pull its US filing for Opdivo plus Yervoy.
Autolus leads winners in spite of scepticism over its CAR-T, and gene therapies disappoint.
The $5bn transaction was surely only made possible by shrinking valuations, but investors in both Glaxo and Tesaro have reasons to be unhappy.